OCX - OncoCyte Corporation Stock Price and Quote

OCX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.66	Insider Own	1.80%	Shs Outstand	118.61M	Perf Week	20.74%
Market Cap	29.62M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	22.52%	Shs Float	106.54M	Perf Month	-19.52%
Income	-64.10M	PEG	-	EPS next Q	-0.09	Inst Own	59.70%	Short Float / Ratio	1.17% / 2.85	Perf Quarter	-6.67%
Sales	8.10M	P/S	3.66	EPS this Y	-57.70%	Inst Trans	-3.83%	Short Interest	1.24M	Perf Half Y	-62.67%
Book/sh	0.65	P/B	0.43	EPS next Y	11.10%	ROA	-40.40%	Target Price	-	Perf Year	-81.46%
Cash/sh	0.31	P/C	0.91	EPS next 5Y	-	ROE	-90.80%	52W Range	0.20 - 1.68	Perf YTD	-12.75%
Dividend	-	P/FCF	-	EPS past 5Y	-11.40%	ROI	-95.70%	52W High	-83.33%	Beta	1.66
Dividend %	-	Quick Ratio	2.80	Sales past 5Y	-	Gross Margin	-8.10%	52W Low	40.00%	ATR	0.05
Employees	110	Current Ratio	2.80	Sales Q/Q	0.00%	Oper. Margin	-	RSI (14)	45.50	Volatility	10.84% 18.52%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	46.60%	Profit Margin	-	Rel Volume	0.86	Prev Close	0.31
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 29 AMC	Payout	-	Avg Volume	436.49K	Price	0.28
Recom	2.60	SMA20	-6.09%	SMA50	-23.52%	SMA200	-55.27%	Volume	375,243	Change	-8.50%

May-24-22

Downgrade

Stephens

Overweight → Equal-Weight

Mar-14-22

Downgrade

KeyBanc Capital Markets

Overweight → Sector Weight

Jan-07-22

Initiated

Stephens

Overweight

$3.10

Jan-06-22

Resumed

Piper Sandler

Overweight

$3.10

Mar-17-21

Resumed

Needham

Buy

Jan-07-21

Upgrade

The Benchmark Company

Speculative Buy → Buy

Dec-16-20

Upgrade

Piper Sandler

Neutral → Overweight

$2 → $4

Nov-30-20

Initiated

BTIG Research

Buy

Nov-10-20

Initiated

KeyBanc Capital Markets

Overweight

Jul-30-20

Reiterated

The Benchmark Company

Speculative Buy

$7 → $6

Show Previous Ratings

Mar-29-23 04:01PM	Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call GlobeNewswire +5.52%
Mar-15-23 04:01PM	Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results GlobeNewswire -20.00%
Mar-02-23 09:00AM	Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer GlobeNewswire
Feb-22-23 08:00AM	Oncocyte Completes Razor Genomics Transaction GlobeNewswire
Dec-16-22 08:19AM	Oncocyte cuts 40% of staff MarketWatch -21.95%
08:00AM	Loading…
08:00AM	Oncocyte Announces Initiatives to Focus Corporate Strategy GlobeNewswire
Nov-30-22 06:05PM	Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors GlobeNewswire
06:00PM	Oncocyte Announces Executive Leadership Changes GlobeNewswire
Nov-10-22 04:30PM	Oncocyte Reports Third Quarter 2022 Financial Results GlobeNewswire
Oct-27-22 04:01PM	Oncocyte to Announce Third Quarter 2022 Financial Results GlobeNewswire -13.50%
Oct-06-22 08:00AM	DetermaIO Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer GlobeNewswire
Sep-07-22 08:00AM	Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS GlobeNewswire
Aug-31-22 04:01PM	Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference GlobeNewswire
Aug-30-22 04:27PM	Oncocyte Announces Five-Year VA Contract for DetermaRx GlobeNewswire -6.93%
Aug-24-22 08:00AM	Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer GlobeNewswire
04:05PM	Loading…
Aug-10-22 04:05PM	Oncocyte Reports Second Quarter 2022 Financial Results GlobeNewswire +10.57%
Aug-03-22 04:01PM	Oncocyte to Participate at Upcoming Investor Conferences GlobeNewswire
Aug-01-22 11:33AM	The past year for OncoCyte (NASDAQ:OCX) investors has not been profitable Simply Wall St.
05:00AM	Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022 GlobeNewswire
Jul-27-22 04:01PM	Oncocyte to Announce Second Quarter 2022 Financial Results GlobeNewswire
Jul-13-22 08:00AM	Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business GlobeNewswire +5.75%
Jul-06-22 08:00AM	Oncocyte Presents DetermaIO Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022 GlobeNewswire
Jun-22-22 08:00AM	Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice GlobeNewswire
Jun-15-22 07:15AM	How Much Of OncoCyte Corporation (NASDAQ:OCX) Do Insiders Own? Simply Wall St.
May-26-22 05:00PM	Oncocyte Presents DetermaIO Data at ASCO 2022 Supporting the Tests Potential to Expand the Clinical Use of Immunotherapy GlobeNewswire
May-11-22 04:05PM	Oncocyte Reports First Quarter 2022 Financial Results GlobeNewswire
May-05-22 08:00AM	Oncocyte Completes Validation of TheraSure Transplant Monitor Test GlobeNewswire
Apr-28-22 04:01PM	Oncocyte to Announce First Quarter 2022 Financial Results GlobeNewswire
Apr-27-22 04:30PM	Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO GlobeNewswire
Apr-22-22 09:26AM	A number of insiders bought OncoCyte Corporation (NASDAQ:OCX) stock last year, which is great news for shareholders Simply Wall St.
10:01PM	Loading…
Apr-13-22 10:01PM	Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire
05:12PM	Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
05:10PM	Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock GlobeNewswire
Apr-11-22 08:00AM	Oncocyte Presents Confirmatory Data for DetermaIO at the American Association for Cancer Research Annual Meeting 2022 GlobeNewswire
Mar-28-22 08:00AM	Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022 GlobeNewswire
Mar-10-22 04:05PM	Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update GlobeNewswire +7.69%
Mar-01-22 04:05PM	Oncocyte to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday March 10 GlobeNewswire
Feb-21-22 07:26AM	Shareholders in OncoCyte (NASDAQ:OCX) have lost 78%, as stock drops 12% this past week Simply Wall St.
Feb-10-22 08:00AM	Oncocyte to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference GlobeNewswire
Jan-18-22 04:05PM	Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology GlobeNewswire +15.87%
Jan-06-22 09:43AM	What Type Of Shareholders Make Up OncoCyte Corporation's (NASDAQ:OCX) Share Registry? Simply Wall St.
Jan-04-22 08:00AM	Oncocyte Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer GlobeNewswire
Dec-09-21 06:00PM	Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocytes DetermaIO Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer GlobeNewswire -9.81%
Dec-08-21 08:00AM	Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx in China GlobeNewswire +10.42%
Dec-06-21 08:00AM	Oncocyte Corporation Hosting Business Update Call GlobeNewswire
Dec-02-21 08:00AM	Oncocyte to Present New Data on DetermaIO Clinical Test for Immunotherapy Response in Triple Negative Breast Cancer at San Antonio Breast Cancer Symposium 2021 GlobeNewswire
Nov-22-21 06:14AM	Is OncoCyte (NASDAQ:OCX) Using Too Much Debt? Simply Wall St. -5.43%
Nov-09-21 04:05PM	Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-21 08:00AM	Oncocyte Announces the Clinical Launch of DetermaIO Immunotherapy Response Prediction Test GlobeNewswire
Nov-02-21 03:02PM	Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-27-21 08:00AM	Oncocyte Strengthens Transplant Intellectual Property Portfolio with US Patent Covering Digital PCR Technology for Early Detection of Organ Transplant Rejection GlobeNewswire -5.00%
Oct-26-21 04:05PM	Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th GlobeNewswire
Oct-08-21 09:46AM	A OncoCyte Corporation (NASDAQ:OCX) insider increased their holdings by 11% last year Simply Wall St.
Oct-07-21 08:00AM	Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer GlobeNewswire
Sep-30-21 08:00AM	Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer GlobeNewswire
Sep-20-21 11:35AM	Oncocyte Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting GlobeNewswire
08:00AM	Oncocyte Hosting Two-Part Key Opinion Leader Event Series GlobeNewswire
Sep-16-21 08:00AM	Modern Healthcare Recognizes Oncocyte as One of the 2021 Best Places to Work in Healthcare GlobeNewswire
Sep-13-21 08:00AM	Oncocyte to Present New Data on DetermaIO from NeoTRIPaPDL1 Trial in Oral Presentation from Late-Breaking Abstract at ESMO 2021 GlobeNewswire
Sep-07-21 04:05PM	Oncocyte to Participate in the 5th Annual Lake Street Capital Markets Best Ideas Growth Conference GlobeNewswire
Aug-23-21 09:13AM	Investors in OncoCyte (NASDAQ:OCX) have made a strong return of 202% over the past year Simply Wall St.
Aug-18-21 08:49AM	Is the Options Market Predicting a Spike in OncoCyte (OCX) Stock? Zacks
Aug-17-21 08:00AM	Oncocyte Launches First Real-World Evidence (RWE) Registry to Evaluate Biomarker Impact on Early-Stage Lung Cancer Treatment Decisions and Outcomes GlobeNewswire
Aug-10-21 04:01PM	Oncocyte Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Aug-09-21 08:00AM	Oncocyte to Participate in Upcoming Investor Events GlobeNewswire
Aug-03-21 03:00PM	Will OncoCyte (OCX) Report Negative Earnings Next Week? What You Should Know Zacks
Jul-27-21 10:35AM	Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10 GlobeNewswire
Jul-08-21 05:34AM	Here's What OncoCyte Corporation's (NASDAQ:OCX) Shareholder Ownership Structure Looks Like Simply Wall St.
Jun-22-21 08:00AM	Oncocyte Celebrates Women Thoracic Surgeons in #ShesMySurgeon Campaign GlobeNewswire
Jun-15-21 08:03AM	EchelonDx and Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offerings Business Wire
Jun-03-21 08:00AM	Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocytes DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally GlobeNewswire +7.97%
Jun-01-21 08:00AM	Oncocyte Selected as New Day One Launch Site for QIAGENs Companion Diagnostics Test to Identify Patients for Amgens Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer GlobeNewswire
May-24-21 05:26AM	Is OncoCyte (NASDAQ:OCX) A Risky Investment? Simply Wall St. -6.65%
May-17-21 04:01PM	Oncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
02:45PM	OncoCyte Corp. to Host Earnings Call ACCESSWIRE
May-06-21 08:00AM	Medicare Coverage Determination for Molecular Testing Announced for Solid Organ Allograft Rejection, Citing Multiple Publications from OncoCyte Corporations Subsidiary Chronix Biomedical, Inc. GlobeNewswire
May-04-21 04:01PM	Oncocyte to Report First Quarter 2021 Financial Results on Monday, May 17 GlobeNewswire -5.51%
03:00PM	Will OncoCyte (OCX) Report Negative Q1 Earnings? What You Should Know Zacks
Apr-28-21 04:31PM	Oncocyte to Present New Data on DetermaIO Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting GlobeNewswire
Apr-19-21 08:00AM	Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc. GlobeNewswire -7.29%
Apr-14-21 09:02AM	Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors GlobeNewswire
Apr-10-21 01:31PM	Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO GlobeNewswire
Apr-06-21 04:05PM	Oncocyte to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-23-21 01:44AM	Ronald Andrews Is The CEO, President & Director of OncoCyte Corporation (NASDAQ:OCX) And They Just Picked Up 11% More Shares Simply Wall St. +12.37%
Mar-16-21 04:01PM	Oncocyte Provides Corporate Update and Reports Fourth Quarter and Annual 2020 Financial Results GlobeNewswire
02:30PM	OncoCyte Corp. to Host Earnings Call ACCESSWIRE
08:00AM	Oncocyte Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types GlobeNewswire
Mar-15-21 08:00AM	Oncocyte To Present New Data at 2021 American Association for Cancer Research (AACR) Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO GlobeNewswire
Mar-09-21 08:00AM	Oncocyte Announces Formation of Medical Advisory Board GlobeNewswire +19.35%
Mar-04-21 08:00AM	Oncocyte Announces Agreement with MultiPlan Network, Expanding Patient Access to DetermaRx GlobeNewswire -9.93%
Mar-03-21 04:01PM	Oncocyte to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 16 GlobeNewswire
Feb-25-21 08:00AM	Oncocyte Closes Second Investment In Razor Genomics to Complete Acquisition GlobeNewswire -8.87%
Feb-23-21 04:05PM	Oncocyte to Begin Trading on the Nasdaq Stock Market on March 8, 2021 GlobeNewswire -6.46%
Feb-16-21 04:05PM	Oncocyte to Participate in Fireside Chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference GlobeNewswire +9.80%
01:24AM	Did OncoCyte Corporation (NYSEMKT:OCX) Insiders Buy Up More Shares? Simply Wall St.
Feb-09-21 04:05PM	Oncocyte Announces Closing of $40 Million Public Offering of Common Stock GlobeNewswire -7.02%
Feb-05-21 06:06PM	Why Oncocyte Shot 13% Higher Today Motley Fool +12.99%
08:25AM	Oncocyte Announces Pricing of $35 Million Public Offering of Common Stock GlobeNewswire
Feb-04-21 04:05PM	Oncocyte Announces Proposed Public Offering of Common Stock GlobeNewswire
Feb-02-21 09:35AM	Oncocyte Acquires Blood-Based Molecular Diagnostics Provider, Chronix Biomedical For Roughly $10 Million Benzinga +8.06%

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Arno Andrew	Director	Dec 23	Buy	0.35	250,000	87,875	532,049	Dec 28 04:05 PM
Gutfreund John Peter	Director	Dec 23	Buy	0.33	75,000	24,728	75,000	Dec 28 04:05 PM
KINGSLEY ALFRED D	Director	Dec 22	Buy	0.28	25,000	7,125	439,111	Dec 27 06:47 PM
ANDREWS RONALD ASBURY	Former CEO	Dec 01	Option Exercise	0.00	250,000	0	583,212	Dec 09 08:23 PM
Last Andrew J.	Director	Aug 17	Buy	0.87	20,000	17,400	70,170	Aug 19 08:00 AM
Arno Andrew	Director	Aug 17	Buy	0.90	15,000	13,500	15,000	Aug 19 08:00 AM
Arno Andrew	Director	Aug 16	Buy	0.97	115,523	112,057	282,049	Aug 17 08:15 PM
ANDREWS RONALD ASBURY	President & CEO	Aug 16	Buy	0.96	40,000	38,400	333,212	Aug 18 04:05 PM
GRIFFITH MELINDA	Director	Aug 16	Buy	1.00	10,000	10,000	30,000	Aug 17 08:18 PM
Carter Jennifer L.	Director	Aug 16	Buy	0.95	10,500	9,975	30,500	Aug 17 08:17 PM
Arno Andrew	Director	Aug 15	Buy	0.93	34,477	32,064	166,526	Aug 17 08:15 PM
Gutfreund John Peter	Director	Aug 15	Buy	0.93	25,000	23,250	25,000	Aug 17 08:19 PM
KINGSLEY ALFRED D	Director	Aug 15	Buy	0.97	10,000	9,700	414,111	Aug 17 08:20 PM
Last Andrew J.	Director	Jun 24	Option Exercise	0.00	10,000	0	40,170	Jul 19 04:05 PM
Arno Andrew	Director	Jun 24	Option Exercise	0.00	10,000	0	122,049	Jul 19 04:05 PM
KINGSLEY ALFRED D	Director	Jun 24	Option Exercise	0.00	10,000	0	394,111	Jul 19 04:05 PM
Carter Jennifer L.	Director	Jun 24	Option Exercise	0.00	10,000	0	10,000	Jul 19 04:05 PM
GRIFFITH MELINDA	Director	Jun 24	Option Exercise	0.00	10,000	0	10,000	Jul 19 04:05 PM
Redmond Cavan M.	Director	Jun 24	Option Exercise	0.00	10,000	0	120,863	Jul 19 04:05 PM
PURA VIDA INVESTMENTS, LLC	10% Owner	Jun 24	Sale	1.03	99,386	102,635	7,427,202	Jun 28 07:48 PM
Yu Li	VP Cntrllr/Prncpl Acctng Offcr	May 18	Option Exercise	0.00	25,000	0	25,000	May 19 05:58 PM
Yu Li	VP Cntrllr/Prncpl Acctng Offcr	May 18	Sale	1.14	8,128	9,266	16,872	May 19 05:58 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Apr 14	Buy	1.33	6,003,752	8,000,000	23,353,697	Apr 15 06:13 PM
PURA VIDA INVESTMENTS, LLC	10% Owner	Apr 14	Buy	1.33	5,931,707	7,887,850	8,532,663	Apr 18 09:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience